Invasive cryptococcosis and adalimumab treatment [9]

Emerging Infectious Diseases

Volumn 13, Issue 6, 2007, Pages 953-955

  Horcajada, Juan P ^a   Peña, Jose L ^a   Martínez Taboada, Víctor M ^a   Pina, Trinitario ^a   Belaustegui, Isabel ^a   Cano, María Eliecer ^a   García Palomo, Daniel ^a   Fariñas, M Carmen ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMPHOTERICIN B; CHLOROQUINE; CORTICOSTEROID; ETANERCEPT; FLUCONAZOLE; FLUCYTOSINE; INFLIXIMAB; METHOTREXATE; PREDNISONE; PYRROLE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CELLULITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG WITHDRAWAL; HUMAN; INFECTION RISK; INFLAMMATION; LETTER; LOW DRUG DOSE; NONHUMAN; OPPORTUNISTIC INFECTION; RHEUMATOID ARTHRITIS; SEROLOGY; TENOSYNOVITIS;

EID: 34250011381     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1306.070154     Document Type: Letter

References (10)

1. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-85.
2. Descalzo MA, Biobadaser Study Group. Spanish registry of adverse events of biologic therapies in rheumatic diseases. (BIOBADASER). Report of the situation on January 2006 [article in Spanish]. Reumatologia Clinica. 2007;3:4-20.
3. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:889-94.
4. US Food and Drug Administration. Arthritis Drugs Advisory Committee: safety update on TNF-α antagonists: infliximab and etanercept. [cited 2007 Mar 13]. Available from http://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b2. htm
5. True DG, Penmetcha M, Peckham SJ. Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. J Rheumatol. 2002;29:1561-3.
6. Hage CA, Wood KL, Winer-Muram HT, Wilson SJ, Sarosi G, Knox KS. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest. 2003;124:2395-7.
7. Shrestha RK, Stoller JK, Honari G, Procop GW, Gordon SM. Pneumonia due to Cryptococcus neoformans in a patient receiving infliximab: possible zoonotic transmission from a pet cockatiel. Respir Care. 2004;49:606-8.
8. Herring AC, Lee J, McDonald RA, Toews GB, Huffnagle GB. Induction of interleukin-12 and gamma interferon requires tumor necrosis factor alpha for protective T1-cell-mediated immunity to pulmonary Cryptococcus neoformans infection. Infect Immun. 2002;70:2959-64.
9. Huffnagle GB, Toews GB, Burdick MD, Boyd MB, McAllister KS, McDonald RA, et al. Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol. 1996;157:4529-36.
10. Buchanan KL, Murphy JW. What makes Cryptococcus neoformans a pathogen? Emerg Infect Dis. 1998;4:71-83.